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Abstract
A significant case report of a HIV infected patient in his fifties who experienced an excellent viro-
logical and immunological response to antiretroviral therapy (which has been modified just to pre-
vent or avoid some adverse events), but developed a severe, sudden acute kidney failure while under 
a polypharmacy due to some underlying and overwhelming disorders (i.e. arterial hypertension, 
non-insulin-dependent diabetes mellitus, a recent acute heart infarction with remarkable remnants, 
and finally an anecdotal muscle-joint pain with self-prescription of non-steroideal anti-inflammato-
ry drugs), represents the key point for a debate around the increasing frequency of “polypharmacy” 
in the field of HIV infection, even when HIV resistance to antiretroviral is not a concern. The con-
tinuing increase of mean age of HIV-infected population, plus the existing, sometimes unmodifia-
ble risk factors for cardiovascular, dysmetabolic, and renal disorders, plus the adjunct of anecdotal 
illnesses prompting the resort to different drugs and medications, either prescribed for HIV infec-
tion itself, or taken for concurrent or subsequent diseases, or self-prescribed occasionally due to an 
intercurrent, trivial disorders per se, may prompt a complicated scenario culminating with a life-
threatening acute renal failure of tubular origin. Our report gives us the opportunity to revise and 
discuss the expected interactions between antiretroviral therapy and the even growing exposure to 
multiple different drug and drug classes, which may be responsible for relevant drug interactions 
and direct or adjunctive end-organ impairment, up to life-threatening conditions, which may be 
avoided or prevented by considering carefully all comorbidites and co-treatments potentially admi-
nistered to HIV infected patients, thirty years after the discovery of AIDS.
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Background
Even though the introduction of the combined antiretroviral therapies (cART) significantly contribu-
ted to a rapid and huge drop of the overall morbidity and mortality rates of HIV disease since around 
15 years ago (year 1996, when the first “triple therapies” containing the HIV protease inhibitors beca-
me available), however we are experiencing an increasing burden of a very broad spectrum of organ 
and tissue damages and/or dysfunctions, often severe and sometimes life-threatening in their clinical 
expression, which appeared to be related to many factors, which are often not independent, one with 
another: HIV infection itself, HIV-related disorders, drugs administered to treat HIV and other admi-
nistered drugs, increased mean age, life-style factors and patient’s genetic background.
The present review aims at discussing the influence of all these factors. The starting point is a clinical 
case report observed by the authors, which gives us the opportunity to revise and discuss the expected 
interactions between antiretroviral therapy and the even growing exposure to multiple different drug 
and drug classes, which may be responsible for relevant drug interactions and direct or adjunctive end-
organ impairment, up to life-threatening conditions, which may be avoided or prevented by conside-
ring carefully all comorbidities and co-treatments potentially administered to HIV infected patients, 
thirty years after the discovery of AIDS.
Some points of discussion emerging from the occurred case report are addressed and commented in 
the following literature review and discussion, which focuses on extremely significant pharmacological 
and nephrological-internal medicine problems encountered in the daily management of HIV disease, 
from a general and broad point of view.
Case report and clinical question
A 51-year-old male patient with a familiar history of cardiovascular disease (but a negligible personal 
and familiar history with regard to diabetes mellitus and nephropathy), who has been smoking around 
20 cigarettes per day since over 30 years, had a history of moderate alcohol intake at main meals (wi-
thout prior or present illicit drug abuse), a body mass index and a waist-to-hip abdominal circumfe-
rence within normal limits, and a mild arterial hypertension treated successfully since around three 
years with the fixed association valsartan (160 mg) plus hydrochlorotiazide (12.5 mg), was incidentally 
diagnosed with an heterosexually-transmitted HIV infection six years and eight months ago, at our 
dedicated outpatient centre. At that time, he felt well, and no relevant clinical problems were present, 
save another sexually-transmitted disease, i.e. a latent syphilis, which was immediately and successfully 
treated with i.m. benzylpenicillin, according to standard indications. 
Soon (12 weeks) after the diagnosis of HIV infection (when his baseline HIV-RNA level was 84,000 co-
pies/ml, and his absolute T-lymphocyte count proved to be 322 cells/µl – 23% of the total T-lymphocyte 
count), a cART regimen was started according with present international guidelines, with associated 
zidovudine-lamivudine (as a fixed combination), plus the fixed protease inhibitor association lopina-
vir-ritonavir (as the standard boosted HIV protease inhibitor, at that time – year 2003). Virological 
success (as expressed by the achievement of undetectable viral load levels, set at < 200 HIV-RNA co-
pies/ml at that time) was attained three months later, while the immunological recovery allowed our 
patient to reach his peak of absolute peripheral CD4+ T-lymphocyte count (626 cells/µl; 26% of abso-
lute T-lymphocytes), compared with the baseline value of 322 cells/µl (23%), 12 months after starting 
the first-line cART regimen.
Subsequently, during a quite long (46-month) period, two therapeutic switches of cART were deemed 
necessary, due to antiretroviral drug(s) intolerance, prevention of expected toxicities, enhancement of 
patient’s convenience, and consequently achievement of the best possible adherence. 
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Neither virologic nor immunological nor clinical failures emerged during this entire period, and no 
HIV-associated disorders of any kind were present or were detected, since ever. 
No prominent toxicities developed during the first cART regimen (zidovudine-lamivudine, plus lopi-
navir-ritonavir), when excluding a mild hypercholesterolemia (maximum serum levels of cholesterol 
220 mg/dl, with HDL cholesterol at 44 mg/dl, and LDL cholesterol 175 mg/dl), mostly prompted by 
lopinavir-ritonavir, and treated successfully with rosuvastatin (at only 5 mg/day), and a more evident, 
lopinavir-ritonavir-linked hypertriglyceridemia (up to 292 mg/dl of serum triglycerides reached six 
months after the introduction of this fixed-dose HIV protease inhibitor combination), successfully 
managed with diet, physical exercise, and polyunsaturated fatty acids supplementation (at 4 g per day), 
only, until values around 200 mg/dl of serum triglyceride levels were steadily maintained. At that time, 
we avoided the administration of fibrates and other hypolipidemic medications registered for the phar-
macological treatment of hypertriglyceridemia, since they are burdened by potentially serious drug-
drug interactions with cART and other concomitant medicines, especially statins.
When coming to the last 22 months, our patient has developed some remarkable and worsening clini-
cal problems, when treated with his fifth cART line. 
In fact, the second proposed regimen, which was a combination of efavirenz plus the fixed nucleoside 
association zidovudine-lamivudine, was not tolerated, due to persistent central nervous system (CNS) 
subjective symptoms, and a hitchy but self-limited maculo-papular cutaneous rash, probably related 
to efavirenz administration, while the nucleos(t)ide backbone, and the other concurrent medications 
remained unchanged. 
At that time, in accordance with novel drug availabilies and the updated antiretroviral therapy guide-
lines, the staff physician of our dedicated HIV outpatient centre recommended the fixed nucleos(t)ide 
association of two nucleos(t)ide reverse transcriptase inhibitors (tenofovir-emtricitabine, 245-200 mg 
once daily), and the protease inhibitor saquinavir (1000 mg twice daily), plus ritonavir booster (100 
mg twice daily). 
Looking for a cART regimen simplification and a reduction of ritonavir booster dosage (which was re-
ponsiblle for a moderate diarrhea and nausea-vomiting), the previous cART regimen was switched after 
nine months in order to introduce another protease inhibitor-based cART (i.e., atazanavir 300 mg once 
daily, plus a “baby”-mimimum dose of ritonavir = 100 mg/day), to support the already effective patient’s 
adherence, to overcome the patient’s “intolerance” to ritonavir, and to reduce the pill burden, too. 
Nine months later, a further protease inhibitor-based regimen (i.e., fosamprenavir 700 mg twice daily, 
plus ritonavir booster 100 mg twice daily) was deemed necessary, after which our patient developed an 
otherwise asymptomatic, but persisting jaundice (which is an expected and characteristic adverse event 
of atazanavir, whose clearance occurs after hepatic glucuroconjugation). Under the atazanavir-based 
regimen, the patient’s serum bilirubin levels rose up to 7,66 mg/dl, and did not decrease significantly 
over three consecutive standard quarterly clinical-laboratory controls made at our outpatient centre.
A slight peripheral (facial and limb) HIV- and cART-related lipoatrophy was present since a couple of 
years, as better depicted by a Dual-Energy X-ray Absorptiometry (DEXA) scan, as mean of excluding 
relevant alterations of bone mineral density, and of ruling out an evident visceral lipoaccumulation.
A severe, sudden thoracic pain occurred when our patient was driving his car, and going to making 
his job. 
It was immediately diagnosed at an emergency unit of another Hospital of Bologna, Italy, as an acute 
myocardial infarction, which required a prompt coronary artery angioplasty with stent placement in 
the left anterior descending coronary artery, and concurrent thrombolytic treatment and clopidogrel 
administration (subsequently followed by the introduction of aspirin at the standard 100 mg/day dose). 
Notwithstanding the rapid and effective cardiologic management, the myocardial infarction resulted 
in a seriously impaired left ventricular systolic function, as expressed by an ejection fraction steadily 
reduced to around 30%. 
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During the subsequent clinical and laboratory follow-up, three months later a mild fasting serum glu-
cose level elevation (121 mg/dl) prompted the timely measurement of HbA1c (7.2%), so that a dia-
gnosis of frank diabetes mellitus was also posed, on the basis of the laboratory control plasma insulin, 
C-peptide, and fructosamine levels. The diagnosis of diabetes mellitus was enforced after detecting 
significant alterations at the standard oral glucose load tolerance testing (OGTT). As a result, a type 
II non-insulin-dependent diabetes mellitus was defined, and a specific diet plus physical exercise pro-
gram (shared with cardiology consultants), and the oral antidiabetic agent metformin (at 850 mg, two 
times a day) were prescribed.
Unfortunately, a concurrent (hypertension-related? diabetes mellitus-related? HIV-related? tenofovir-
related? multiple drug-related? accelerated atherogenesis-related?), apparently slight “nephropathy” 
was disclosed for the first time, based on a protein-creatinine ratio of 1.2, whereas the kidney function 
appeared still fully preserved, as assessed on the ground of trivial serum creatinine levels ranging from 
0.8 to 1.1 mg/dl in two laboratory controls obtained in one week, and creatinine clearance values va-
rying from 85 to 99 ml/min, while serum and urine electrolytes, serum osmolarity, and all the other 
parameters of urinalysis, remained within standard limits for the entire observation period.
Beyond the well established and well tolerated antiretroviral therapy steadily performed with tenofovir/
emtricitabine plus fosamprenavir/ritonavir, which ensured a persistingly stable virological suppression 
(viral load always <50 HIV-RNA copies/ml), and a perfectly maintained immune system recovery (as 
expressed by a CD4+ cell count persistingly beyond 550 cells/µl, with the CD4+ lymphocyte rate always 
over 27%), after the mentioned examinations and the novel diagnoses, multiple medications were ad-
ded, upon specialistic consultation with cardiologists, diabetologists, and nephrologists, which were 
promptly ensured during the first week following the patient’s recovery from the acute heart infarction, 
and his subsequent hospital discharge. 
These medications were: metformin (850 mg twice daily) for the recently diagnosed non-insulin-de-
pendent diabetes mellitus type II, plus aspirin (100 mg/day), carvedilol (12.5 mg twice daily), enalapril 
(2.5 mg twice daily), and furosemide (at 25 mg once daily), for the underlying, and very recent heart 
ischemic injury with notable post-infarction remnants, the appearance of very mild (almost negligible) 
disorders of kidney function, and the already known arterial hypertension, which always remained per-
fectly under control (with the former valsartan/hidrochlorotiazide therapy interrupted, when a beta-
blocker, plus an ACE-inhibitor, plus a mild dose of the most common renal loop diuretic furosemide 
were added), upon triple cardiologic-diabetologic-nephrologic specialistic consultancies were obtained. 
During the next five months, our patient remained substantially stable, save the need of a mild increase 
of metformin dosage (prescribed at 500 mg thrice daily, at main meals), in order to keep serum HbA1c 
always within its normal threshold, associated two months later with a doubled furosemide dosage 
(25 mg twice daily), in order to control a mild edema of lower limbs, probably related to the patient’s 
prolonged standing, when at work. 
At that time, a repeated heart ultrasonography showed for the first time an impairment of the right ven-
tricular function, while the ejection fraction of the left ventricle remained substantially stable (around 
30%).
Suddenly and unexpectedly, 13 days after his previous scheduled consultation at our outpatient centre 
and his antiretroviral drug refill and careful check of all concurrent drug prescriptions and medica-
tions, our patient after calling us by telephone, came directly to the Hospital, asking for an urgent visit. 
He complained of deep asthenia, generalized malaise, polypnea and nausea without fever, vomiting, 
and other thoracic and gastrointestinal signs and symptoms, lasting and progressing since three days. 
After telling (among others), that he strained his back during the past week when at work, he declared 
the spontaneous assumption of over-the-counter ibuprofen (already present at patient’s home), taken 
at a dosage varying from 400 to 800 mg/day for five consecutive days. Notwithstanding a complete 
rest recommended by the primary care physician, and his self-medication with an over-the-counter 
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NSAID, he has felt progressively worse and worse, until the above-mentioned request of an urgent 
outpatient visit.
Our patient was initially visited by the physician in charge at our HIV outpatient centre, and showed 
a substantially negative physical examination, when excluding a frank polypnea (25-30 breaths per 
minute) and a clearly accelerated arterial pulse rate (120 per minute), but hemoglobin O2 saturation 
tested 99% without oxygen therapy, and neither increased body temperature, nor an abnormal arterial 
blood pressure, were present. The electrocardiography assay tested comparable with previous controls 
(i.e. a prevalence of left ventricle potentials over right ones, a probable mild right atrium enlargement, 
plus aspecific repolarization alterations, in absence of any ischemic sign). 
In a few minutes, we rapidly moved to our Day-Hospital rooms.
At this facility of ours, it was possible to make an urgent, standard chest X-ray examination, and an 
abdominal ultrasound assessment (which did not show significant abnormalities, when excluding a 
mild enlargement of the heart frame, without any alteration of great vessels of lung parenchyma, and 
pleura, and especially intrabdominal organs, with special attention deserved to kidneys and urinary 
tract), together with an urgent blood and blood gas examination, which was technically executable at 
our Day-Hospital also after the scheduled early morning time established by our Hospital reference 
laboratory for the standard outpatient subject controls (i.e. 9:00 am). 
Early in the afternoon, the urgent laboratory values of our patients were as follows: serum glucose 133 
mg/dl, serum creatinine 1.19 mg/dl, blood urea nitrogen 81 mg/dl, sodium 139 mEq/l, potassium 6.5 
mEq/l (while all other available hematological and biochemistry analyses, including serum troponin, 
myoglobin, and creatinphosphokinase levels, proved perfectly normal). The patient’s urgent urinalysis 
did not show albumin, urinary tract cells, red and white blood cells, and bacteria, fungi, or crystals, the 
urine pH was 7.5, but specific gravity tested slightly low: i.e. 1.009. An arterial blood gas examination 
made concurrently with the other urgent laboratory tests, due to persisting dyspnea and hyperventila-
tion, without any very significant clinical and radiological clue, detected: normal pO2 and pCO2 values, 
while bicarbonates proved 14.1 g/dl (i.e. features suggestive of metabolic acidosis). Serum lactates were 
not required, while further laboratory examinations (including i.e. the potentially relevant serum/urine 
phosphate rate, other serum/urine electrolytes, and serum osmolarity) could not be measured immedia-
tely, since they are not included in the panel of “urgent” basic laboratory examinations which may be per-
formed “as default” tests in non-hospitalized patients, and answered in 90-120 minutes time maximum. 
Immediately after preliminary laboratory examinations became available on the internal web network 
of our University Hospital (S. Orsola-Malpighi, Bologna, Italy), the patient was hospitalized at our 
inpatient Division in the early evening of the same day, for further examinations and treatment, as 
appropriate.
During the next few hours, when all pharmacological treatments had been temporarily withdrawn, the 
diagnosis of metabolic acidosis of suspected “renal” origin was confirmed. Elevated serum lactate levels 
(41 mg/dl) were disclosed by standard examinations, with a relevant hypokaliemia (serum potassium 
2.9 mmol/l) with a concurrent, mild hypophosphoremia, and slightly reduced serum calcium levels, 
while urinalysis showed a prominent increase of potassium, phosphorus, and calcium concentration, 
with a lowered output of sodium and chloride.
During the first 24-36 hours of hospitalization, serum kidney enzymes (i.e. serum creatinin, urea, and 
uric acid levels), moderately worsened, but they were rapidly corrected by a prompt supportive care 
(progressive fluid refill, and bicarbonate and electrolyte administration titred every 2-6 hours on the 
ground of clinical and laboratory testing and urinalysis), while all vital parameters and the hourly urine 
output remained within normal limits. A complete resolution was attained in the subsequent 72 hours 
(at the sixth day since admission), which was followed by the expected a 5-7-day-long hypostenuric 
polyuria which reflected the temporarily impaired tubule function due to the sudden, extensive renal 
tubule necrosis occurred one week before. After 12 comprehensive days of hospitalization, our patient 
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was discharged without any kind of renal function sequelae, which did not appear during the subse-
quent, 16-month follow-up, until now.
In early March, 2011, our patient is still stable on his novel cART association including: the fixed dose 
tenofovir/emtricitabine (at one pill, once daily), re-introduced one week after discharge, and the pro-
tease inhibitor darunavir (at 800 mg once daily), plus ritonavir (at 100 mg/daily), which replaced the 
previous protease inhibitor association of fosamprenavir plus ritonavir. In particular, tenofovir (as well 
as all other concurrent medications) had been withdrawn upon hospital admission, but it was safely 
re-introduced only one week after discharge without any other clinical and laboratory problem in the 
subsequent 16-month follow-up, while acting as a potent, safe, and convenient once-daily therapy in 
its fixed-dose backbone combination with emtricitabine. Concurrently, the protease inhibitor daruna-
vir, recently approved as a first-line choice also in patients without previous virological failures, was 
successfully introduced without any significant adverse event of any kind, as checked for the same 
16-month observation period. The fixed “backbone” association of tenofovir/emtricitabine was there-
fore maintained (depending on a careful and strict patient’s monitoring in the first weeks), since its use 
was weighted against the potential risks of the other available fixed associations of nucleos(t)ide ana-
logue backbones, i.e. that of abacavir plus lamivudine, and that of zidovudine and lamivudine. When 
selecting a “third” agent, in order to “restore” a “classical” triple cART combination in a patient who 
achieved a complete and sustained virological response to all previous cART combination thanks to his 
100% adherence to all regimens, never experienced a virological and/or immunological and/or clinical 
failure in his entire life, and was invited or “forced” to switch even five times his previous “classical” 
cART regimens due to mild and/or transient adverse events, and/or aiming to further improve the 
patient’s convenience and to reduce the global pill burden, a rechallenge with another non-nucleoside 
reverse transcriptase inhibitor was avoided (due to previous patient’s intolerance to efavirenz), so that 
the last-generation once-daily protease inhibitor darunavir was selected, since it perfectly conjugates 
an elevated potency, a high genetic barrier to HIV mutation and resistance, and enhanced dysmetabo-
lic, end-organ, and also renal safety profile, especially when given as a single daily dose of 800 mg only, 
plus the less possible ritonavir booster dosage (100 mg/day). In early March 2011 our patient is still 
on his last tenofovir-emtricitabine plus darunavir-ritonavir cART, he maintains a steadily suppressed 
HIV viremia (plasma HIV-RNA levels <50 copies/ml), and an absolute CD4+ lymphocyte count of 
602 cells/µl concurs (i.e. 28% of absolute peripheral T-lymphocytes), at our last available clinical and 
laboratory control of February 27, 2011. 
With regard to the multiple, concomitant medications which played a life-saving role in our patient 
(all major non-HIV-related disorders!), since over 16 months ago we confirmed rosuvastatin (at 5 mg/
day) to maintain serum total cholesterol levels and cholesterol fractions under the enforced thresholds 
for patients who already experienced a major cardiovascular event, plus omega-3 polyunsaturated fatty 
acids (always at 4 g/day), from the dysmetabolic point of view, and as a part of a mandatory secondary 
cardiovascular prevention subsequent to a the major accident (the prior acute heart infarction). When 
considering the stable left heart ventricle impairment established in our patient, a treatment with the 
ACE-inhibitor ramipril (5 mg/day), the beta-blocker metoprolole (at 100 mg daily), plus low-dosage 
furosemide (25 mg/day), and aspirin (100 mg/day) was successfully continued without any clinical 
and/or laboratory disturbance, together while low-dose pioglitazone (15 mg/day only), which was se-
lected instead of metformin as an oral antidiabetic drug for the underlying non-insulin-dependent 
diabetes mellitus, which remained perfectly under control from a clinical, laboratory, and instrumental 
point of view (with regard to serum glucose levels, Hb1c threshold, urinalysis, and ophthalmologic and 
neurological examinations carried our by our consultants). Over the entire observation period which 
followed the discharge from our inpatient service (over 16 months ago), the patient’s kidney function 
remained perfectly stable and within normal limits, and microalbuminuria and other diabetes- and 
hypertension-related disorders never appeared in our quarterly laboratory and clinical controls.
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Discussion
Causes of kidney failure in HIV patients
Causes can be summarized as follows:
 • HIV infection itself, including directly- and indirectly-mediated organ and tissue damage [1-11]; 
 • HIV-related disorders, which showed a dramatic decline of their incidence and overall progres-
sion and mortality rates just during the cART era, thanks to the effective antiviral activity of cART, 
and the immune recovery prompted by the same highly active anti-HIV treatments. However, an 
increasingly modified disease presentation, which may lead to a true “pathomorphism” of infec-
tious, neoplastic, and other HIV-related and AIDS-related and unrelated disorders in an increasing 
number of cases, has been recognized just since the cART era. As known, this relevant phenome-
non has emerged in parallel with the use of effective and potent cART regimens, and it may be attri-
butable to a very extensive number and variety of concurrent, and not always independent factors 
and co-factors [8,12-20], including immune recovery achieved just thanks to cART itself [21,22], 
and worldwide epidemiological changes (due to huge immigration flows, for example) [23]. At 
the same time, the number of “AIDS presenters”, i.e. the subjects in whom HIV disease has been 
detected concurrently with one or more AIDS-defining disorders, is increasing worldwide, and has 
become an extremely worrying clinical and especially public health concern, in its dimensions and 
implications [12-15,18,24-27];
 • the role of administered drugs, and especially that determined by cART itself, and their multiple, 
varied, and often associated organ and tissue toxicities, which add to pre-existing HIV- and non-
HIV-correlated disorders and their respective pharmacological treatments [1-5,8,10,18-20,28-47]. 
The so-called “lipodistrophy syndrome” is one of the key features also heralding a significantly gre-
ater risk of cardiovascular and other end-organ events, including vascular structure and function, 
bone and mineral metabolism, with kidney function obviously interested [20,48-51];
 • other medicines of any kind, prescribed with an increasing frequency over years and especially 
during the cART era, in an increasing proportion of patients, also to prevent or manage the exten-
sive toxicities of cART itself and that of other, concomitant medications [3,6,7,8,10,18,28-33,39,44-
46,52-63] (Table I);
 • lifestyle-related relevant population-based [64,65], or individually recognized factors, including 
i.e. cigarette smoking, illicit or recreational drugs use, alcohol intake, lack of an appropriate diet 
and physical exercise, i.e. a broad series of “unmodifiable” and “modifiable” risk factors for cardio-
cerebrovascular damage and other potentially severe end-organ disorders among HIV-infected pa-
tients, as known since many years [8,10,61,66-68];
 • the progressively increased mean age of the entire population living with HIV, which unavoidably 
predisposes to further comorbidities and to an exponential increase of nested disorders, as well as 
the expected cumbersome problems linked to their prevention, monitoring, and management in 
the daily clinical practice of physicians engaged in the care of people affected by HIV disease, even 
more during the third millennium [4,5,7,8,10,18,19-22,27,28,34-36,41-43,61,69,70];
 • the genetic background of patients, taken as racial- and gender-related issues, and indivi-
dual features, which may influence and affect all the above-mentioned causes and correlations 
[10,18,21,22,70-75].
ART regimens and renal function
With regard to renal function and kidney disorders, all approved cART regimens according to the 
present, updated 2010-2011 guidelines, regardless of their composition, significantly reduce the overall 
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mortality and deaths related to all severe kidney diseases in patients with HIV infection. However, the 
proportion of chronic and end-stage renal disease seems on the rise over time just from the early cART 
era – year 1996) [6, 7,18-20,43,47,62,76]. For instance, the so-called “HOPS cohort” study which inclu-
ded nearly 7,000 HIV-infected patients followed per a median time of over 39 months, showed that the 
proportion of deaths involving kidney disorders significantly increased from the year 1996 to 2004 [7].
Consequently, the cumulative risk of developing either acute or chronic renal injuries, and subsequen-
tly end-stage renal disease in a non-negligible proportion of patients, remains proportionally elevated. 
Moreover, these kidney disorders are probably missed or diagnosed late and underreported (especially 
when mild events are of concern), and remain largely underestimated in current clinical practice. In 
addition, cART itself and the role of underlying diseases and that of concomitant medications, may 
contribute to bias this figure in any possible direction. Anyway, early, borderline, subtle, or near-negli-
gible abnormalities of renal function parameters and serum-urine electrolyte levels may be detected 
frequently during the overall natural history of HIV disease, even more among patients receiving 
cART regimens, and further more when other diseases and other medications, or lifestyle or elderly 
themselves, are of some concern [5,6-8,10,18,19,21,22,28,36,42,43,46,54,61-63,76], so that it becomes 
exceedingly difficult to distinguish between “para-physiological” conditions prompted by occasional 
circumstances (i.e. a trivial dehydration occurring during a hot Summer, and the paradoxical immune 
recovery prompted by cART itself) [21,22], and subtle abnormalities which may precipitate into a full-
blown renal or end-organ disorder, which may sometimes prompt a life-threatening event [63,77,78].
Tenofovir
Tenofovir disoproxil fumarate (briefly, tenofovir), has been discovered through a collaborative research 
project between Antonín Holý at the Institute of Organic Chemistry and Biochemistry, Academy of 
Sciences of Prague (Czech Republic), and Erik DeClercq, of the Rega Institute for Medical Research, 
at the Catholic University of Leuven, Belgium. Tenofovir has been approved by the United States Food 
and Drug Administration (FDA) on October 26, 2001, for the treatment of HIV infection [10,79], and 
nearly 7 years later (on August 11, 2008), for the treatment of chronic hepatitis B [80,81]. Tenofovir is 
a first-choice nucleoside reverse transcriptase inhibitor for the treatment of HIV infection in the large 
majority of current therapeutic lines, because of its intrinsic antiviral potency, its safety profile, its con-
venient once-daily dosage (also as fixed combination with emtricitabine, and even more as a triple fixed 
association including the first-choice non-nucleoside reverse transcriptase inhibitor efavirenz), and its 
elevated potency against HBV infection too, which is a frequent comorbidity just relevant for patients 
living with HIV infection [10,43,76,80-82]. 
The “intrinsic” tenofovir-associated nephrotoxicity has been extensively and quite well studied 
[10,18,43,47,62,74-76,79,83,84]. Like other nucleos(t)ide analogues, tenofovir requires intracellular 
phosphorilation to become pharmacologically active, and at the cell level several different drug carriers 
may act on the intracellular concentration and disposition of all these drugs [74]. In particular, tenofo-
vir transportation occurs through proximal tubular cells, by the action of four so-called organic anion 
transporters (OATs), whose types 1 and 3 are mostly involved for drug uptake. The renal elimination 
of tenofovir is provided by a cluster of 14 multi-drug resistance-associated proteins (MRPs), the most 
relevant of which are MRP-2 (also called ABCC2), and MRP-4 (also named ABCC4) [74]. Notably, just 
MRP-2 activity is blunted by the HIV protease inhibitor ritonavir (regardless of its dosage, i.e. 100 mg/
day as atazanavir or darunavir booster, or 400 mg/day as tipranavir booster). Furthermore, several ge-
netic polymorphisms of these transporters may affect their function, with unpredictable consequences 
on intracellular tenofovir concentrations, and its directly related toxic effects [74,75].
The kidney toxicity of tenofovir usually involves the proximal tubule function, but other mechanisms 
prompted by the frequent underlying comorbidities and related polypharmacology, and the increasing 
life expectancy of subjects living with HIV may reveal, unmask, increase, complicate, and finally lead 
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to an acute kidney failure, or to a progressive renal damage evolving into an end-stage kidney disease, 
which either could not be prevented, or had been previously neglected, or has not been discovered 
earlier, due to an endless number of possible causes and interferences [5,8,10,18,19,36-45,57-63,85-87]. 
When associated with the other nucleos(t)ide analogue emtricitabine (in the mentioned fixed combi-
nation), or with lamivudine as a first-line nucleos(t)ide analogue backbone component of a “classical” 
cART regimen [82], largely employed also in HIV-HBV-co-infected patients, and also when admini-
stered to HBV-mono-infected patients [81, 82, 89], tenofovir results safe in the large majority of cases. 
This concept remains true when tenofovir is used alone, as well as when it is prescribed in combination 
with HIV non-nucleoside reverse transcriptase inhibitors (like efavirenz, nevirapine, and etravirine) 
[88], and novel-class anti-HIV agents like integrase inhibitors (i.e. raltegravir and elvitegravir), entry 
inhibitors (like maraviroc and vicriviroc), and fusion inhibitors (like enfuvirtide). On the other hand, 
some nucleos(t)ide analogues (like didanosine, whose plasmatic levels increase upon co-administa-
tion wih tenofovir) [10,38], and also the antiviral ribavirin for the treatment of chronic hepatitis C 
[69,89-92], the “older”, intrinsically nephrotoxic protease inhibitor indinavir [44,45,93,94], as well as 
the presently used first-line protease inhibitor-based cART regimens (especially those including rito-
navir booster), might add subtle, but sometimes significantly kidney toxicity concerns [10,18-20,37-
39,43-45,60,62,71,76,85,86,88,93,94]. The “intrinsic” (pharmacologically determined), but somewhat 
negligible and reversible tenofovir nephrotoxicity, could be also enhanced by concomitant disorders, 
and even more by many concurrent medications chronically or acutely prescribed (or spontaneously 
taken by patients themselves), for their known, underlying chronic disorders (either associated with 
HIV disease and cART itself, or not), their age-related disorders, or their occasional, mild-to-moderate 
intercurrent or incidental illnesses, even trivial in relevance (but treated with either prescription me-
dications or self-prescribed, over-the-counter drugs, like the non-steroideal anti-inflammatory drugs 
– NSAIDs) [10,18,19,43,60,76,93].
HIV acute nephropathy
The most severe HIV-associated nephropathy (the so-called HIV acute nephropathy, or “HIVAN”), 
is found in the majority of cases among Africans and African descents, usually shortly after acqui-
ring HIV infection, which has been hypothesized to act directly or indirectly on this vital organ [3,6-
9,63,95]. HIVAN shows a rapid progression to end-stage renal disease when antiretroviral therapy is 
not available, or is not given promptly. As expected, the administration of cART is known to reverse 
the natural history of HIVAN, but the kidney benefits of cART may not be limited to HIVAN only. Un-
fortunately, we are aware that cART is often underprescribed or incorrectly dosed or taken non only in 
developing countries, just where HIVAN is more frequent [63,95], but also in industrialized countries 
[96,97], even more in persons with chronic kidney disorders, with or without a concurrent HIV disease 
[10,18,19,83,95,98]. 
As anticipated, the direct effects of HIV infection on the kidney sum up with a varied genetic background 
and an extremely broad spectrum of immune-mediated factors, physiological conditions like pregnancy 
[75], and especially underlying comorbidities, immune recovery due to cART itself [10,21,22,63], and 
especially overwhelming (also non-HIV associated) diseases, the frequent chronic co-infections (i.e. 
chronic hepatitis B, D, and especially C) [90-92], but also an increasing prevalence of sexually-transmit-
ted diseases including syphilis [24,99-101] (as in our case), and even hepatitis A [102]. 
As expected, the extremely different medications prescribed (or self-prescribed, or taken in a not ap-
propriate, even “heterodox” mode by HIV-infected patients themselves) [28,83,96-98,103] have their 
intrinsic toxicities but they also have potential, varied drug-drug interactions among an almost endless 
list of drugs potentially used (or useful, or needed, or taken as “recreational” ones) by individuals living 
with HIV, even more in the years 2010-2011, when the life expectancy of HIV-infected individuals is 
approaching that of the general population (Table I) [5,8,18,27,36,42,67]. 
92 Reviews in Health Care 2012; 3(2) © SEEd All rights reserved
Kidney failure during HIV disease treated with tenofovir, multiple concurrent diseases and drug therapies
This explosive “polypharmacy” typical of a growing rate of patients living with HIV disease, may 
prompt a proportionally enlarged spectrum of end-organ damages, also including serious kidney di-
sorders, too [5-7,10,18,19,36-43,54,57-63,66,69,76,85,86], just at a greater extent among HIV-infected 
individuals, who already suffer from their expected problems of prompt recognition, expert diagnosis, 
careful clinical and laboratory management, strict monitoring, and possibly “proactive” prevention 
measures of all toxicities and adverse events, which could be avoided or blunt as far as possible 
[8,10,18,19,62].
In our specific case report, and in our specific situation, we have to review some key points of interest 
for either specialists of different medical specialties, and practitioners (family care physicians):
Familiar background
Some familiar background for cardiovascular diseases as a whole (which is very common in the general 
population of North-Eastern Italy – Emilia-Romagna region, whose capital city is Bologna) [64,65], 
some relevant lifestyle habits (i.e. cigarette smoking since many years, moderate alcohol consumption 
at major meals), but still normal body mass index and waist-to-hip circumference, an already establi-
shed essential arterial hypertension successfully treated, followed by a sudden, overwhelming major 
heart event such as an acute myocardial infarction with important end evolving sequelae, plus the 
“incidental discovery” of a type II, non-insulin-dependent frank diabetes mellitus, deserving oral anti-
diabetics only, is the “evolving clinical picture” of our unfortunate patient;
Lifetime pharmacological treatments
The requirement of multiple, chronic (quoad vitam, i.e. lifetime) pharmacological treatments, inclu-
ding common anti-hypertensive drug combinations (which had been switched from the former ba-
Drugs




Other associated  
abnormalities
TMP-SMX (Bactrim®) +++ Hyperkalemia, crystalluria
β-lactams ++
Sulfadiazine ++ Crystalluria, nephrolithiasis
Fluoroquinolones + 
Rifampin + + Hypokalemia, hypouricemia, hypernatremia, vasculitis
INH + Overdose leads to high anion gap metabolic acidosis
NSAIDs +/− + Proteinuria, secondary minimal change disease, 
papillary necrosis
Dapsone +/− Papillary necrosis
Amphotericin B +++ Hypokalemia, hypomagnesemia, hypernatremia, NDI
Pentamidine +++ Crystalluria, hyperkalemia
Foscarnet +++ Hypercalcemia/hypernatremia, Glomerular crystals
Ganciclovir + 
Acyclovir + +/− Crystalluria
Indinavir, atazanavir + Crystalluria, nephrolithiasis
Abacavir +/−
Tenofovir ++ Fanconi, NDI
Table I. Selective drugs causing AKI in HIV-infected patients [104]
+ = mild injury; ++ = moderate injury; +++ = severe injury; INH = isoniazid; NDI = nephrogenic diabetes 
insipidus; SMX = sulfamethoxazide; TMP = trimethoprim
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seline valsartan/hidrochlorotiazide association towards a beta-blocker plus an ACE-inhibitor, intro-
duced after the acute myocardial infarction and successfully maintained after the acute episode of the 
described kidney insufficiency), the mandatory adjunct of 100 mg aspirin after the acute myocardial 
infarction with relevant sequelae, and the continued, very simple loop diuretics (like furosemide in our 
case, whose initial dosage had been initially increased due to a mild, concurrent edema of lower limbs 
of non-nephrogenic nature, and then continued also after the acute kidney failure at lower dosage), as 
well as oral antidiabetic agents (with the intercurrent resort to an increased dosage of metformin, in 
order to maintain our patient within the desirable Hb1c threshold just before his “critical” episodes of 
acute renal failure).
The oral antidiabetic therapy was subsequently changed towards the more recent oral thiazolidine-
dione insuline-sensitizing agent pioglitazone, administered at its lower dosage of 15 mg/day. This oral 
antidiabetic agent has been selected with careful attention after and instead of previous metformin 
therapy, since it was thought to add something to recover (and maybe prevent?) the HIV- and cART 
related peripheral lipoatrophy (which is part of the very common lipodistrophy syndrome of many 
patients living with HIV, but was present in a very mild form in our patient) [49,105-107]. Since accor-
ding to a recent meta-analysis, the “cousin” thiazolidinedione rosiglitazon, which showed a very signi-
ficant activity in recovering just tenofovir nephrotoxicity [91], but has not demonstrated significantly 
greater beneficial effects on the lipodistrophy syndrome over both pioglitazone and especially metfor-
min [106], pioglitazone seems safer in patients burdened by a high cardio-cerebrovascular risk (like 
our patient), although the previously employed metformin proved the only insulin-sensitizer agent 
which has been demonstrated to partly improve visceral fat accumulation, serum lipid profile, and also 
endothelial function in the general population (but no data are available until now in HIV-infected pa-
tients). Anyway, we decided to favor pioglitazone (and not rosiglitazone), in our patient, who received 
it at the same dosage for over 16 consecutive months obtaining a full control of his diabetes mellitus, in 
absence of significant adverse events (including the already present mild limb edema, which remained 
unchanged despite pioglitazone therapy, which has lower limb edema listed among its potential side ef-
fects). A substantially stable peripheral lipoatrophy picture, and no osteopenia, as detected by a DEXA 
scan repeated 12 months after the first one, were found at our periodical clinical controls. This last drug 
choice (that of oral pioglitazone) shows how it may become cumbersome (but also very satisfactory for 
both caregivers and patients), to individualize, even to “tailor” the care of every HIV-infected patient 
according to his/her background, present problems, and future criticisms and strategies [8,48,50,108].
Among hypolipidemic drugs used for the concurrent, high-risk dyslipidemia in a patient with a major 
previous heart event, rosuvastatin was maintained at the same low dosage, due to its combined efficacy-
tolerability issues just in high-risk HIV-infected patients undergoing cART [53,55,101,109], as well as 
an isolated adjunct of a titred dosage of n-3 polyunsaturated fatty acids, which have been approved just 
in the prevention of major cardiovascular events [30,52,56,66], and preferred to fibrates in our case [29].
The “unavoidable” combined anti-HIV medications (cART), couldn’t be stopped since mid-2008, but 
only simplified as far as possible [82], even though the virologic-immunologic target have been reached 
and have been maintained under complete control for a long term. With regard to acute or chronic-
progressive loss of renal function in persons living with HIV and taking cART, tenofovir was the only 
known “intrinsically” nephrotoxic anti-HIV agent taken by our patient before its episode of acute kid-
ney failure, but it was carefully re-challenged and proved perfectly safe in our case (until a 16-month 
follow-up period after the acute episode), and played its key role in both prior and subsequent triple 
“classical” cART regimens, even after the acute kidney injury episode [5,8,10,18,19,36,37-44,47,57-
63,85,86,110].
The described episode of acute-onset kidney failure might have been favored by a broad spectrum of 
causes acting concurrently with HIV itself, and all underlying and overwhelming diseases, to lead at 
some point to a somewhat “critically” impaired renal activity [111], which may be followed by a po-
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tentially life-threatening “cascade” of events, such as metabolic acidosis and lactic acidosis plus hypo-
kalemia and other potentially severe electrolyte and acid-base status imbalances [110,112], which are 
already well known adverse events of many HIV-associated medications [10,18,32,54,62], and may 
be prompted by the concurrent (ab)use of very common drugs, including trivial diuretics and some 
anti-hypertensive compounds, as well as oral antidiabetics like metformin, and NSAIDs at least. Just 
these insuline-sensitizing drugs are of extremely frequent use in the metabolic syndrome and related 
issues [48,50,113], where a sort of “vicious circle” is already of concern among metabolic alterations, 
insulin resistance, vessel and kidney injuries, pro-inflammatory cytokine cascade, an extensive and 
generalized “endothelitis”, accelerated atherogenesis, finally followed by a global premature aging, cha-
racterized by an exponentially increased risk of developing life-threatening acute- or chronic-onset 
end-organ damages, like an “explosive” mixture, which is presently the major concern in people living 
with HIV [1,2,8,10,18,19,42,43,48,49,62,66,76]. 
In fact, the readers may easily imagine what will happen when all these related and unrelated condi-
tions are becoming more and more common and severe, just among HIV-infected patients treated with 
cART, while these patients are increasing their mean age and their comorbidities, towards their elderly 
[3-5,10,18,19,30,31,35,36,40-42,49,56,60,62,63,69,86].
Differential diagnosis
When trying to establish a differential diagnosis in a HIV-infected patient with an acute, sudden loss of 
kidney function while under cART, and concurrent diseases with their related, multiple medications, 
first of all we have to proceed as in the general population with a somewhat matched age, clinical and 
pharmacological background [18,19,62,69,77,78,93]. Therefore, we have to take into careful considera-
tion all the endless concomitant conditions which may characterize or modify the kidney disease pre-
sentation and course, when HIV infection, comorbidities, antiretroviral drugs, and polypharmacy are 
of serious concern in age-comparable patients with some commonly encountered underlying diseases.
Initially, it remains mandatory to detect whether the renal damage is primarily located in the renal 
glomeruli, or in the kidney tubules. Since abdominal ultrasonography studies are not expected to show 
relevant abormalities (as in our case), on the ground of a very trivial urinalysis (which did not show 
albumin or erythrocytes in the presented case), it is not wise that we are fronting a sort of “mainly” 
glomerular lesion (although our patient was already affected by a known essential arterial hyperten-
sion, and by a “more recent” major heart event, which represented the most relevant “clue” of a genera-
lized, elevated risk of accelerated atherogenesis, possibly prompting other vital organ damages, as well 
as a “recently” diagnosed non-insulin-dependent but frank diabetes mellitus, requiring oral antidiabe-
tic drugs, which also represent the worse “companion” of the metabolic syndrome, in terms of a frankly 
increased cardiovascular risk). As a consequence, already at the “glomerular” level, we wonder how 
many inter-reacting pathological conditions might have the kidney as the predestined target “victim” 
of such an “obscure conspiracy”, which kept our patient under threat (Figure 1).
After ruling out a significant “glomerular” involvement on the ground of extensive clinical and labora-
tory examinations (a GFR of 83 ml/min was calculated upon patient’s admission, together with a crea-
tinine clearance of 103 ml/min), a simple urinalysis, and a monitoring of urine output, subsequently it 
becomes appropriate to move immediately our attention on other causes and mechanisms which may 
affect the renal function through an injury at the “tubular” level.
When examining the differential diagnosis of our patient’s acute kidney injury as a potential conse-
quence of “tubular” more than “glomerular” damage, the clinical pathway must be approached using 
the “classical” nosology of “prerenal”, “intrarenal”, and “postrenal” causes [77,78]. A typical prerenal 
cause of acute kidney failure usually include the conditions where some cause of volume depletion is 
of concern. This could descend from multiple pathological conditions, and it may often be the “very 
trivial” consequence of an exaggerated diuresis, potentially due to a disproportionate loss of fluids, but 
Figure 1. Standard monitoring of kidney function in HIV infected patients
95Reviews in Health Care 2012; 3(2)© SEEd All rights reserved
R. Manfredi, L. Calza, V. Colangeli, N. Dentale, G. VerucchiKidney failure during HIV disease treated with tenofovir, multiple concurrent diseases and drug therapies
it may be also due to both left and right heart ventricular dysfunction (extensively determined at the 
left side, but just in its initial stage at right heart ventricle in our patient, as assessed by a recent ultraso-
nography examination). But the origin may be “iatrogenic”, of course:
 • a simple, not-well tailored resort to long-term loop diuretics (with furosemide recently increased 
in its dosage, in our patient); 
 • the concurrent administration of slightly nephrotoxic drugs, like the recently introduced anti-
hypertensive ACE-inhibitor and the oral antidiabetic drug metformin (as in our patient, too);
 • on a long-term scenario, the virologically and immunologically effective and nephrologically “si-
lent” tenofovir-containing very common cART regimen (the first-line fixed association of tenofo-
vir-emtricitabine as the most prescribed antiretroviral backbone in the common clinical practice) 
[10,18,62,82]. 
Based on the lack of initial, significant alterations of laboratory kidney examinations, and especially the 
urinalysis of our patient, an “intrarenal” cause of the acute failure would suggest to focus attention on 
the kidney tubules, at first. An acute tubular injury is caused by a severe cell toxicity, usually respon-
sible of an equally acute tubular necrosis. The potential causes of a sudden, acute tubular necrosis in 
our case patient might include an extremely wide spectrum of conditions. After excluding the most 
common post-renal cause (the obvious bladder outlet obstruction), a pre-renal cause has to be seeked: 
a cART regimen including tenofovir should be the apparent “major” target for a proportional narrow 
knowledge of a HIV/AIDS or a clinical infectious disease specialist, also due the well known “intrinsic” 
kidney toxicity of tenofovir [10,18,37,43,62,76,79,83,85], but… since “Internal Medicine” must be the 
founding ground of the entire Medicine, we have to consider carefully and promptly all the multiple 
concomitant conditions and medications, and we have also to look immediately for any possible kind 
of jatrogenic damage. Actually, a proportionally mild (but critical) volume depletion resulting in a 
proportional hypotension but without a repeated heart ischemic injury (excluded at first clinical exa-
tentially life-threatening “cascade” of events, such as metabolic acidosis and lactic acidosis plus hypo-
kalemia and other potentially severe electrolyte and acid-base status imbalances [110,112], which are 
already well known adverse events of many HIV-associated medications [10,18,32,54,62], and may 
be prompted by the concurrent (ab)use of very common drugs, including trivial diuretics and some 
anti-hypertensive compounds, as well as oral antidiabetics like metformin, and NSAIDs at least. Just 
these insuline-sensitizing drugs are of extremely frequent use in the metabolic syndrome and related 
issues [48,50,113], where a sort of “vicious circle” is already of concern among metabolic alterations, 
insulin resistance, vessel and kidney injuries, pro-inflammatory cytokine cascade, an extensive and 
generalized “endothelitis”, accelerated atherogenesis, finally followed by a global premature aging, cha-
racterized by an exponentially increased risk of developing life-threatening acute- or chronic-onset 
end-organ damages, like an “explosive” mixture, which is presently the major concern in people living 
with HIV [1,2,8,10,18,19,42,43,48,49,62,66,76]. 
In fact, the readers may easily imagine what will happen when all these related and unrelated condi-
tions are becoming more and more common and severe, just among HIV-infected patients treated with 
cART, while these patients are increasing their mean age and their comorbidities, towards their elderly 
[3-5,10,18,19,30,31,35,36,40-42,49,56,60,62,63,69,86].
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When trying to establish a differential diagnosis in a HIV-infected patient with an acute, sudden loss of 
kidney function while under cART, and concurrent diseases with their related, multiple medications, 
first of all we have to proceed as in the general population with a somewhat matched age, clinical and 
pharmacological background [18,19,62,69,77,78,93]. Therefore, we have to take into careful considera-
tion all the endless concomitant conditions which may characterize or modify the kidney disease pre-
sentation and course, when HIV infection, comorbidities, antiretroviral drugs, and polypharmacy are 
of serious concern in age-comparable patients with some commonly encountered underlying diseases.
Initially, it remains mandatory to detect whether the renal damage is primarily located in the renal 
glomeruli, or in the kidney tubules. Since abdominal ultrasonography studies are not expected to show 
relevant abormalities (as in our case), on the ground of a very trivial urinalysis (which did not show 
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glomerular lesion (although our patient was already affected by a known essential arterial hyperten-
sion, and by a “more recent” major heart event, which represented the most relevant “clue” of a genera-
lized, elevated risk of accelerated atherogenesis, possibly prompting other vital organ damages, as well 
as a “recently” diagnosed non-insulin-dependent but frank diabetes mellitus, requiring oral antidiabe-
tic drugs, which also represent the worse “companion” of the metabolic syndrome, in terms of a frankly 
increased cardiovascular risk). As a consequence, already at the “glomerular” level, we wonder how 
many inter-reacting pathological conditions might have the kidney as the predestined target “victim” 
of such an “obscure conspiracy”, which kept our patient under threat (Figure 1).
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tory examinations (a GFR of 83 ml/min was calculated upon patient’s admission, together with a crea-
tinine clearance of 103 ml/min), a simple urinalysis, and a monitoring of urine output, subsequently it 
becomes appropriate to move immediately our attention on other causes and mechanisms which may 
affect the renal function through an injury at the “tubular” level.
When examining the differential diagnosis of our patient’s acute kidney injury as a potential conse-
quence of “tubular” more than “glomerular” damage, the clinical pathway must be approached using 
the “classical” nosology of “prerenal”, “intrarenal”, and “postrenal” causes [77,78]. A typical prerenal 
cause of acute kidney failure usually include the conditions where some cause of volume depletion is 
of concern. This could descend from multiple pathological conditions, and it may often be the “very 
trivial” consequence of an exaggerated diuresis, potentially due to a disproportionate loss of fluids, but 
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mination and ECG examination, as well as after serum troponin and heart enzymes testing), although 
relevant heart failure remnants were present and well documented in our case, as shown by an already 
severe, but stable left ventricle heart damage, and an initial right ventricle impairment, was detected 
at the last heart ultrasonography. In the mean time, the use of loop diuretics in association with ACE-
inhibitor antihypertensive agents and a very common antidiabetic agent like metformin (whose dosage 
had been just increased to reach the normal HB1c threshold), unadvertently led our patient to a sort 
of “blind alley”.
So that finally, the somewhat occasional intake of a very common over-the-counter NSAID (i.e. ibu-
profen, in our case), for an intercurrent, trivial back pain, became of major concern in our unfortunate 
case, when compared with all other “competing” causes of an acute renal injury, which added signifi-
cantly one together with the other one, although every single drugs played a near negligible intrinsic 
kidney damage. 
A quite remarkable laboratory finding in the patient’s urinalysis, which deserves an enhanced value 
when re-reading carefully our case report, was the specific gravity tested at 1.009. The lowest th-
reshold of specific gravity of 1.005 usually indicates the most diluted urines, while a specific gravity 
of 1.030 represents the most concentrated ones. When other renal lesions are excluded (or played a 
non-significant role, as in our case), the kidneys in their attempt to preserve both intravascular vo-
lume and serum sodium levels do excrete concentrated urines (up to a specific gravity of 1,030). The 
value observed in our patient (i.e. 1.009) is therefore named isosthenuria, since urine concentration is 
within normal limits. The presence of an isosthenuria reflects tubules that have neither concentrated 
nor diluted the urine, but this issue occurs in a very “critical” patient with a correct fluid balance (as 
assessed by the urgent, laboratory examinations available at that time at our Day-Hospital facility), 
but rapidly shifting towards a potentially life-threatening metabolic acidosis and hypokalemia, follo-
wed by a precipitous worsening of kidney function abnormalities in the early hospitalization period, 
luckily corrected by the prompt detection of a severe metabolic acidosis of renal origin, and timely 
monitorized and treated as appropriate. As a consequence, when in the clinical setting of an acute 
kidney injury, it is mandatory to exclude or confirm a phenomenon of acute tubular necrosis, and its 
expected consequences.
When considering the “last straw of a pot already filled to the brim”, in our “especially unfortunate”, 
but finally even “lucky” patient, a major role has been probably played just by the most commonly 
used drugs all over the world, i.e. the NSAIDs, which are well known as prescribed but (even more…) 
as over-the-counter and even more self-prescribed medications burdened by non-negligible toxicity 
[114], and sometimes used also by patients with suicidal behavior [115], similarly to an episode due to 
a probable long-term repeated prescription (a sort of “self-prescription” of immunosuppressive drugs 
with lethal outcome), which was described by us five years ago [98].
In the field of potential nephrotoxicity due to NSAIDs [93,114], we have to consider the primary me-
chanism of action of these drugs: they substantially blunt the synthesis of prostaglandins (i.e. the ma-
jor elements of inflammation as a whole), but also lead to a concurrent action on vasoconstricting 
hormones, such as angiotensin in the renal scenario. The expected consequence of decreasing kid-
ney perfusion becomes more evident among the different kinds of volume-depleted patients, through 
adjunctive mechanisms of either vasodilation, or impaired/reduced heart function, which leads to a 
further reduction of the perfusion pressure. These subjects actually “rely” on their prostaglandins all 
day round, in order to try “manage” their renal perfusion as far as possible. When prostaglandins are 
inhibited by NSAIDs (and similar drugs) for example, the renal function of individuals with an arterial 
volume depletion becomes proportionally volume-sensitive: at this “delicate” time, very subtle or near 
negligible, and apparently “minor” changes in global volume may become responsible of large decrea-
ses of renal perfusion. Like the events due to an absolute volume depletion (easy to rule out in our case 
report), the decrease in perfusion at some critical point is expected to result in a transition phase, from 
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the kidney “asking for sodium” and conserving the volume, to an apparently sudden and unexpected 
kidney “displacement”, when an impaired perfusion reaches a critical threshold, and finally turns into 
the occurrence of a true, full-blown tubular cell necrosis, and immediately thereafter in an acute kidney 
injury [77,78,93]. As perfectly known by everybody in the field of Internal Medicine, the concurrent 
administration of a common ACE-inhibitor antihypertensive like enalapril (taken at standard dosage 
by our patient, before and after his acute renal “crisis”), and a similar common resort to furosemide and 
metformin, further “confuse” this already cumbersome scenario (if possible), by making the patient 
even more and more susceptible to otherwise minimal volume changes.
As anticipated, nephrotoxicity is a well known but quite uncommon and usually reversible complica-
tion of tenofovir administration for both HBV and especially HCV chronic infection [19,37-39,43-
45,60,69,76,85,86,93], which may possibly be prompted when other anti-HIV nucleos(t)ide analogue 
(i.e. didanosine) [38], and maybe when the anti-HCV ribavirin [69,89] are co-administered.
Actually, the renal spectrum of adverse effects of the “intrinsically” nephrotoxic tenofovir [10,18,19,37,39, 
40,43,47,57-60,62,63,76,79,83,85,86], classically includes: 
 • the potentially serious but reversible Fanconi’s syndrome, similar to inherited or other disease-
related (especially malignancy-related) multiple end-organ dysfunctions [116], characterized by an 
excessive tubular loss of glucose and/or electrolytes and/or albumin, and associated with hypokale-
mia and hypophosphoremia) [10,37,39,85];
 • infrequent, mostly anecdotal cases of acute kidney failure (like ours), resembling Fanconi’s disea-
se in their clinical onset, presentation, and outcome [10,18,19,38,40,57,59,60,62,76,85,86]; in fact, 
the renal alteration completely recovered, and the re-challenge with another tenofovir-containing 
cART regimen proved safe for the entire follow-up period;
 • also extremely rare cases of diabetes insipidus, of renal origin obviously [39]. 
To complicate this already cumbersome clinical picture, we have to remind that these rare toxicities 
have been reported within one month and up to 15 months after the initiation of a tenofovir-inclu-
ding therapy for whatsoever indication [10,18,47,62,63,69,76,81,82,84]. Anyway, both observational 
studies and registrative clinical trials estimate the rate of impairment of renal function among pa-
tients receiving tenofovir to be approximately 1% of cases, mostly reversible in a limited temporal span 
[10,18,19,38,47,57-60,62,63,76,84-86]. 
However, the pathogenetic pathway by which tenofovir may be linked to an acute kidney injury, other 
than by an histopathological demonstration of the so-called “kariomegaly” [59], has not reached to the 
best of our knowledge. As a trivial deduction, and because of the infrequent availability of systematic 
histopathological examinations of these anecdotal cases, it becomes possible that an elevated propor-
tion of acute kidney injuries involving patients on tenofovir do not include tenofovir itself as the “ma-
jor” causative agent, as previously anticipated.
Even though the risk factors for these proportionally uncommon kidney toxicities are still not perfectly 
estimated in their frequency and known in their “crossing” and “shared” pathogenetic mechanisms 
[10,18,19,38,44,45,57,59,60,62,63,71,76-78,85,86,93,94], data extrapolated from randomized clinical 
trials, small case series, and anecdotal reports have suggested that probably a broad series of factors 
may play a role in supporting this acute condition in some selected subjects, burdened by several, easily 
recognizable risk factors [10,19,59,69,77,78,85,93]: 
 • an already existing impairment of renal function (which was absent in our case, but may be 
prompted by an accelerated atherogenesis, a pre-existing arterial hypertension, the overwhelming 
acute heart infarction and the diabetes mellitus of novel diagnosis);
 • a lower body weight (it was not the case of our patient, too);
 • a lower absolute CD4+ T-lymphocyte count (also absent in our otherwise unfortunate patient, du-
ring all his entire follow-up period);
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 • the concomitant resort to other “severe, intrinsic” nephrotoxic antiretroviral medications, with re-
gard to the antiretroviral nucleos(t)ide analogue didanosine [38], and the well-known “intrinsical-
ly” nephrotoxic protease inhibitor indinavir [10,44,45,93,94], as well as other antimicrobial agents 
of extensively common use among HIV-infected patients (i.e. ribavirin, adefovir, ganciclovir, cido-
fovir, foscarnet, aminoglycosides, amphotericin B, pentamidin, vancomycin, teicoplanin, interleu-
kin-2, and many others), but our patient never received these drugs in his proportionally “recent” 
history of asymptomatic HIV disease, so that he never underwent treatments with other frankly 
nephrotoxic compounds [7,8,10,18,19,25,59,61,62,68,69,80,81,89], and did not suffer of chronic he-
patitis B or C, which are frequent events in HIV-infected individuals [28,69,89-92].
With regard to the second of the four identified risk factor, a missed renal impairment affecting for 
example a person with a reduced skeletal muscle mass may result in a potential mediator of even severe 
nephrotoxicity. That is to say, a serum creatinine value of 1.1 mg/dl in an around 60-year-old female 
patient with a body weight of 60 kg would result in a calculated creatinine clearance of slightly more 
than 50 ml/min. In this example, failure to recognize promptly “borderline” serum creatinine levels of 
around 1.0 mg/dl, might lead to the administration of a disproportionally elevated tenofovir dosage, 
and finally to an increased risk of renal function impairment [10,18,19,37-40,60,62,85,86].
The expected (and repeatedly announced previously), potential contributors to tenofovir-related 
renal toxicity include the physician’s prescription of NSAIDs, or the “self-prescription” of over-the-
counter NSAIDs [93], as well as multiple concurrent medications including antiretrovirals themsel-
ves, antimicrobial agents, and all the “politherapy” used to manage the adverse events of cART itself 
[5-7,10,18,19,36,37-43,46,54,57-62,76,85,86,92], as well as the role played by the concurrent immune 
recovery in supporting “paradoxically” greater immune-mediated pathogenetic mechanisms [22,63].
NSAIDs are well known and very widely administered pharmacologic agents, which are burdened by 
risks of inducing an acute kidney failure [93], even independently of the concomitant employment of 
other nephrotoxic drugs. Small but significant case series demonstrated that acute kidney failure may 
occur in patients who concomitantly receive both tenofovir and NSAIDs [10,18,19,43,60,76,93].
As a matter of fact, from a clinical point of view the still incomplete pathogenetic pathway of all drug-
drug associations capable to “fire up” an acute renal damage in these complicated-to-manage patients 
[10,18,19,44,45,62,63,76-78,93] does not change the “bedside” management in the field of medicine, 
which plays a critical role in its promptness, but does not need specific measures according to the ma-
jority of potentially involved drugs. In fact, after a timely diagnosis (plus a very basic kidney ultrasono-
graphic assay), and thanks to a prompt and adequate delivery of supportive care, the great majority of 
these acute cases recover spontaneously. 
The problem remains regarding how to move in the next future: in our specific case, it was somewhat 
diffucult to answer the question whether tenofovir should be re-introduced or not, after complete re-
covery of an episode of acute kidney injury prompted by multiple, and continuously “moving” and 
correlated and overlapping causes and medications. Of course, during the acute phase of an acute renal 
failure of still uncertain origin, all drugs which are expected to induce or worsen renal impairment, to-
gether with all medications and “recreational drugs” which that are mainly cleared by the kidney, have 
to be immediately discontinued, as a first prudential measure [18,19,62,63,67,77,78,93].
Furthermore, since we still cannot weigh how elevated is the incremental risk associated with the con-
current administration of all the above-mentioned drugs in combination with each other, when giving 
always a strict priority to patient’s safety, the caregivers of all patients with HIV disease who are recei-
ving tenofovir (and also those with chronic hepatitis B treated with tenofovir, more than the “cousin” 
low-dosage and less nephrotoxic adefovir) [10,80,81] should keep their best careful consideration on 
how to manage trivial, intercurrent conditions like inflammation and pain, in patients under continued 
tenofovir therapy for their potentially severe, chronic viral diseases, like HIV and HBV infection, and 
related disorders and comorbidities.
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Conclusions
Our case report is a contemporary “portrait”, which is a truly representative figure of a subject living 
with HIV and successfully continuing his well tolerated cART regimen, just in the years 2010-2011 (i.e. 
27 years after the discovery of HIV as the agent of AIDS) [117].
Incidentally diagnosed with an asymptomatic, heterosexually-transmitted HIV disease together with 
a concurrent latent syphilis, our patient was already in his fifties, and had some familiar and lifestyle 
“stigmas” which are very common in our general population, and even more in the general population 
of HIV-infected patients, which is becoming more and more older due to two apparently opposite phe-
nomenons: the previously diagnosed subjects living with HIV now reach their elderly thanks to cART, 
while we have a growing number of individuals with a missed or neglected HIV disease until their 
elderly [3-5,18,25,30,31,35,36,40-42,56,60,62,63,69,86].
Our exemplary patient obtained a rapid, complete, and sustained virological response to his early and 
subsequent cART regimens, whose five changes were all due to tolerability/convenience issues, in 
absence of any failure and viral resistance, as expected due to the present availability of over 20 antire-
troviral compounds, and multiple first-choice drugs belonging to many antiretroviral classes [10,82]. 
Moreover, when compared with his several underlying and overwhelming disorders, no HIV-related 
pathologies (including very minor and indirectly-related ones) were detected at any time during a 
yearly clinical follow-up, save mild, transient, and self-limiting adverse events due to some cART regi-
mens (i.e. CNS disturbances and rash attributable to efavirenz introduction, and later hyperbilirubine-
mia due to the typical metabolic-elimination pathway of the HIV protease inhibitor atazanavir) [82].
Taking into account of the increased (and increasing) life expectancy of patients living with HIV (now 
approximating that of the general population), it is more and more necessary to consider adequately 
all the long-term consequences of cART and underlying, also HIV-unrelated disorders, when mana-
ging HIV-infected patients who cannot anymore stop or interrupt their cART treatment [82,118,119], 
due to the documented increase of early life-threatening events observed in a short time after therapy 
discontinuation, and probably mediated by a cytokine cascade prompting cardio- and cerebrovascular 
events, and also end-organ failures, which are caused by the same vicious circle which is primarily cau-
sed by the renewed replication of HIV [1,2,66,82,118-120], although the conclusions emerging from 
some multi-cohort and post-hoc analyses should be considered carefully [121,122], when translated 
into daily clinical practice, and especially when incorporated into the updated guidelines for HIV dise-
ase management [82], which become the reference aid for drug prescription worldwide.
Among end-organ (vital organ) toxicities, the kidney toxicity must be carefully assessed, especially in 
patients with a history of cardiovascular or renal disease itself, those exposed to nephrotoxic drugs 
presently or in the past, patients with comorbidies involving the kidney, or patients who are simply over 
their fifties [3-5,8,10,30,31,35,36,40,43,56,60,78,86,93], as our representative case report tells.
Furthermore, our case report recalls and underlines the multiple mechanisms by which various medi-
cations may interact in the strictest definition of the term, may play a negative, additive or synergistic 
toxic effect towards one or multiple organs and tissues, or result in a trivial rise of some (apparently) 
isolated kidney function parameters, as an early clue of a slow- or rapid-onset kidney toxicity, but may 
also represent the very initial sign of an acute kidney failure, or that of a progression towards a chronic 
renal failure when a pre-existing renal impairment is already present or has been neglected or missed 
in the past. As expected, both acute and chronic kidney failure are life-threatening conditions, in their 
potential short- and long-term evolution, through multiple and often not necessarily related pathoge-
netic pathways [3-5,10,18,30,31, 35,36,41,42,56,60,62,63,69,86].
Since the patients living with HIV are going to reach the same life expectancy of the general popula-
tion, but are prone to a sort of “accelerated aging” (also due to multiple, often unrelated mechanisms) 
[2,5,8,9,36,42,69,123], therefore they are expected to develop worsening comorbidities, and these sce-
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narios are expected to become increasingly common and intricated, and will come to the attention of 
specialists other than infectious diseases ones, in their progressive steps of their multiple underlying 
or concurrent morbidities. From the viewpoint of a multidiscliplinary, “super-specialistic” appraisal 
to these patients [8,10], we underline the need of a careful monitoring of renal function in all patients 
living with HIV, and especially in those treated with cART. 
In stable, HIV-infected patients undergoing cART therapy without any relevant comorbidities and co-
medications, this monitoring should be started at least with a longitudinal assessment of glomerular 
filtration rate (GFR), creatinine clearance, and urine protein and electrolyte contents. Otherwise, the 
rare, but life-threatening episodes of metabolic or lactic acidosis, which are associated with a concur-
rent, severe impairment of renal function and significant electrolyte imbalances, should be recognized 
and managed as early as possible [5,6,8,10,32,33,36,54]. In stable patients, as in the general population, 
the GFR test is much more accurate, when compared with the less sensitive serum creatinine levels, in 
monitoring the kidney function, and even more to catch the very early and mild abnormalities of renal 
function which may precede a full-blown chronic (but also a sudden and acute) kidney dysfunction, 
as happened in our case. A tenofovir-related nephrotoxicity should be addressed when we observe a 
reduction of GFR exceeding 50%, and/or when serum creatinine clearance levels drop of 25 ml/min 
or more. We retrospectively did not find any significant variation of both kidney function parameters, 
when comparing the values detected during hospitalization, with all the available quarterly outpa-
tient clinical controls of our patient. However, when selecting and applying the GFR calculation in the 
estimated prediction of renal function, we have to take into careful account both age and gender, and 
also the race (for the Modification of Diet in Renal Diseases – MDRD – equation), while we have to 
consider the body weight (for the Cockcroft-Gault – CG – equation). Significant distortions of GFR 
measurements are expected to occur, despite substantially similar serum creatinine values, should all 
these variable are not accounted for [124,125].
Regardless of the main (or predominant) etiology of an eventual, acute kidney injury, in subjects living 
with HIV as well as in the general population matched for age, gender, and race, an appropriate diagno-
stic and therapeutic pathway should include: 
 • the assessment, the management, and the removal (if possible), of all risk factors, whether primary, 
secondary, or potential in origin, along with the provision of a prompt and appropriate supportive 
care, should an acute problem is of concern. Some causes of acute renal failure can be diagno-
sed through trivial blood tests, such as rhabdomyolysis using serum creatinine phosphokinase and 
myoglobin levels [33,77,78], which may be performed on “urgent” basis at our outpatient facilities, 
as opposed to urine electrolyte levels and serum electrolytes other than sodium, potassium, and 
calcium, which require a specific over-the-phone contact between the physicians in care and the 
Central Laboratory of our Hospital, based on clinical suspicion, and a 24-hour collection and sto-
rage of urine, which is not applicable in very urgent circumstances;
 • unfortunately in most cases of acute-onset renal failure the initial trigger factor cannot be identi-
fied, or depends on multiple, associate conditions (as in our representative patient). A renal biopsy 
will demonstrate some non-specific cellular damages characteristic of acute kidney injury, and may 
help in ruling out an interstitial nephritis, which has been also recognized as a potentially severe 
renal toxicity prompted by cART [18,63, 108,126]. However, also histopathological studies cannot 
allow us to identify the primary or the direct cause of a sudden kidney function failure, in the large 
majority of cases [77,108,127,128]. However, from a strictly clinical and management point of view, 
the specific identification of the source and the pathological picture are not required to physician in 
charge of such a medical emergency, given that non-specific supportive (although intensive) mo-
nitoring and treatment are always indicated, as a matter of urgency. In the reported patient of ours, 
the initial discontinuing of tenofovir was appropriate not only because of potential role of this drug 
in causing a (rare) acute-onset kidney failure (similar to Fanconi’s disease in its clinical features), 
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but also because of the drug’s prolonged half-life, which is expected during a potentially severe 
renal insufficiency [10,18,43,62,63,76,79,83]. In addition, it seemed essential to discontinue imme-
diately the anti-hypertensive ACE-inhibitor drug [128], the loop diuretic furosemide, obviously the 
NSAIDs [10,18,19,43,60,76,93], and maybe metformin too [129,130], which may be associated with 
severe lactacidemia, regardless of its intrinsic renal safety profile [130]. The therapeutic approach 
is focused on providing a well “tailored” intravascular fluid intake and control, and to re-calibrate 
all fluid and electrolytes delivery on the basis of a continuous clinical and laboratory monitoring. 
 • an extremely careful attention to all kidney function parameters, i.e. at least creatinine clearance, 
GFR, urinalysis, all possibly serum and urine electrolytes (especially serum potassium and phospha-
te levels, as in our case) should be ensured and monitorized at least every 2-3 months to all patients 
taking tenofovir for either HIV or chronic HBV infection, when they are fully stable from a clinical 
point of view. A tenofovir-related nephrotoxicity should be addressed when we observe a reduction 
of GFR exceeding 50% of previously checked levels, and/or when serum creatinine clearance values 
drop of 25 ml/minute or more: it was not the case of our patient, whose glomerular function remai-
ned substantially preserved, despite his already treated arterial hypertension, the acute myocardial 
infarction with a reduced left ventricle injection fraction, and his revent, overwhelming diabetes 
mellitus. On the other hand, when an acute-onset kidney failure or a sudden, unexpected reduction 
of kidney function occur, current laboratory testing should be performed on an emergency basis, 
together with an arterial blood gas analysis, and serum lactic acid, and all serum and urine elec-
trolyte determination: in fact, an unexpected hypophosphoremia may prompt a more severe kidney 
dysfunction in patients receiving tenofovir versus abacavir as their nucleos(t)ide analogue backbo-
ne [87]. In a situation of acid-base derangement like that of our critically ill patient, urinary density 
measurement proved useful to assess the disorders of water balance and to discriminate between 
prerenal azotemia and acute tubular necrosis, and to prompt the immediate resort to supportive life 
measures, and more sophisticated laboratory examination, carried out as soon as possible.
 • in the understanding of the intricated pathogenetic and clinical pathways potentially involving the 
kidneys and their function (including the genetic determinants of multiple possible kidney fun-
ction alterations, which cannot be explored in the current clinical practice) [74,75], it is mandatory 
for all caregivers of HIV disease and all specialists involved with their consultancy, to be aware of 
the management of multiple comorbidities together with HIV (and/or HBV) infection, which are 
becoming more and more easy to be controlled (HIV infection) or cured in the majority of cases 
(chronic hepatitis B), in their well established virological, immunological, clinical and instrumental 
parameters, when compared with all the emerging problems in the field of “polypharmacology” 
used daily to manage concurrent diseases, or even to blunt expected cART toxicities, for example, 
which are becoming a major target of attention of all clinical infectious diseases specialists, since 
over 15 years, just the era of the so-called “higly active antiretroviral therapy” or HAART, presently 
called cART [1,3,5,10,13-15,18,19,28-33,35,36,46,52,53,55,56,62,103].
 • when considering the underlying, antiretroviral therapy [82], which cannot be interrupted but only 
simplified due to an increased risk of disease progression or other life-threatening disorders [118-
120], we have to consider that the different cART regimens are well characterized by a proportio-
nally different renal metabolism and excretion, and this issue must addressed in order to “tailor” the 
best therapeutic choice of cART, in patients who are at risk of developing renal impairment, had a 
prior episode of renal toxicity (as in our case), or may experience a worsening of their pre-existing 
chronic renal disease [8,10,18,19,62]. As anticipated, an increased risk of a progressive decline of 
kidney function over a proportionally prolonged time span (as opposed to the above-mentioned 
acute kidney failure of our patient) has been observed in HIV-infected patients treated with te-
nofovir as a part of the nucleos(t)ide backbone (especially with the non-recommended use with 
didanosine) [38], and the negative pharmacokinetic interactions with abacavir, which did not show 
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an in vivo additive effect to tenofovir [131]. However, when selecting a “traditional” nucleos(t)ide 
analogue backbone for our patient, abacavir-containg combinations have been excluded after a 
careful, collegial discussion, since:
 • our patient already experienced an allergic reaction to efavirenz, and we are aware that some 
hypersensitivity reactions to abacavir may occur also in the absence of the specific genotyping 
testing [71,72];
 • moreover, abacavir administration has been linked in some studies (but it led to a fierce, endless 
discussion according to other data, which primed the so-called endless “abacavir saga”) [122, 
123] to an overall increased, global cardiovascular risk [119,120], so that it was “probably” to 
avoid in our patient, who suffered of a recent acute heart infarction, even though the two availa-
ble fixed dose combinations tenofovir-emtricitabine and abacavir-lamivudine, proved a similar 
virological activity in both antiretroviral naïve and experienced patients [47,82,87,132,133], al-
though patients on a tenofovir- versus abacavir-containing regimen showed an increased risk of 
kidney dysfunction, as recently underlined in the “ASSERT” study, which addressed just serum 
hypophosphoremia as a serious “clue” of an incipient renal toxicity in patients taking tenofovir-
emtricitabine, as opposed to those treated with abacavir-lamivudine, with all enrolled patients 
taking efavirenz as the “third” drug of their cART regimen [87].
 • however, our 16-month-long “re-challenge”, carried out successfully just with the same fixed-
dose tenofovir-emtricitabine combination, confirms the safety of tenofovir, also after an acute, 
but reversible kidney function damage prompted by some other concurrent toxicity factors [10
,18,19,38,40,57,59,60,62,76,85].
 • on the other hand, we have plenty of data regarding the safe use of a “classical” triple cART 
containing a tenofovir-based background, plus either a non-nucleoside reverse transcriptase 
inhibitor, or a boosted protease inhibitor, as the so-called “third drugs”. As known, when exclu-
ding indinavir, nelfinavir, and unboosted fosamprenavir and atazanavir, all other available HIV 
protease inhibitors need a variable dosage of ritonavir boosting [82]. Regardless of ritonavir 
booster dosage, all available protease inhibitors may non-negligibly increase the kidney toxici-
ty of a tenofovir-containing cART, even though this phenomenon becomes clinically relevant 
only when other underlying diseases, supporting factors, and polypharmacy are of concern 
[10,18,19,37,38-41,43-45,47,60,62,63,69,71,76,85,86,88,93,94]. The majority of authors reported 
a negligible, but not unsignificantly increased toxicity at the renal level when patients receiving 
a tenofovir-containg backbone have been compared with those who were treated with tenofovir 
with either emtricitabine or lamivudine, together with a non-nucleoside reverse transcriptase 
inhibitor at a some extent [10,47,71,88], or those who took a cART which did not include teno-
fovir at all [10,40]. To add even more confusion, some preliminary findings were not supported 
by the figures obtained in the “HOPS” study: in this case, the concomitant administration of 
tenofovir and a boosted protease inhibitor did not show relevant changes of kidney function, 
versus HIV-infected patients receiving tenofovir alone [7,41]. Since the a robust evidence is not 
available to prompt avoidance of concurrent use of a boosted protease inhibitors together with 
tenofovir (a very common cART regimen, in our daily clinical practice, as recommended by 
the present guidelines of HIV treatment [82,88]) an increased surveillance of kidney function 
in patients who undergo all these agents concomitantly seems absolutely needed, as well as the 
attention of infectious diseases and HIV/AIDS specialist, added to that of specialist consultants 
(especially nephrologists, cardiologists, and diabetologists, as in our case). 
In our special case report, waiting for a large employment of nucleos(t)ide sparing cART regimens and 
that of regimens completely relying on agents other than nucleos(t)ide and non-nucleoside analogue 
reverse transcriptase inhibitors, which are still not so widely employed in patients showing an excellent 
and sustained response to other cART regimens [82], due to their still incomplete indications and often 
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elevated costs [11,133-135], we had to select 
which was the most effective, and “comfortable” 
classic third agent for our patient. Since we were 
forced to eliminate immediately all available 
non-nucleoside reverse transcriptase inhibitors 
due to the former adverse cutaneous and CNS 
reaction to efavirenz, and a large portion of HIV 
protease inhibitors remained fully effective to 
our unfortunate patient, who never failed a 
cART regimen in his prolonged follow-up, in 
order to accompany the finally maintained teno-
fovir-emtricitabine nucleos(t)ide backbone, we 
selected the effective, safe, and convenient daru-
navir (at 800 mg once daily) plus a minimum 
ritonavir booster dosage (100 mg), after consi-
dering that the acute kidney event occurred un-
der fosamprenavir-ritonavir combination, the 
atazanavir-ritonavir association was not tolera-
ted due to a trivial but persistant hyperbilirubi-
nemia, lopinavir-ritonavir has a well known un-
favorable dyslipidemic profile, and novel profi-
les of risk are at the horizon in patients receiving 
protease inhibitor-based cART regimens [136], 
but may be controlled by statins, too, especially 
when a patient at very elevated risk of repeated 
major vascular events is of concern. As known 
since many years, the HIV protease inhibitors 
may be easily “sequenced” on both a tolerability 
and an efficacy point of view [137-139]. The in-
trinsic renal safety of darunavir itself and the 
smallest required dosage of ritonavir (100 mg 
only), also when combined with tenofovir-
emtricitabine [140], is expected to outweight the 
already modest risk of adjunctive toxicity at the 
renal level which remains a shared feature of all 
HIV protease inhibitors [10,18,19,37,39,43-
45,60,62,63,71,76,85,86,88,93,94], together with 
the slightly increased cost of this last protease 
inhibitor, which has been recently approved also 
for first-line naïve patients, and in its once-daily 
dosing. However, in these patients with pre-
vious, current and future risk of end-organ inju-
ry, the raising funding and pharmacoeconomic 
issues should leave the place to a fair, patient-
oriented, ethical approach to medicine 
[22,27,50,73,141].
Among factors which are known to predict acute-onset or to worsen a pre-existing kidney toxicity, a 
previous experience with any kind of cART act negatively by itself, and especially when well-known 
Take-home messages and questions 
for further researches
• Pay maximum attention to “all” drugs 
and drug combinations with a renal me-
tabolism and/or excretion
• For HIV-infected patients already expe-
rienced with any cART regimen, this con-
dition poses some increased risk of kidney 
and other end-organ toxicity “per se”
• The mechanism of kidney toxicity may be 
different, according to the different drugs 
concurrently administered just to patients 






 ∙ protease inhibitors (with focus on rito-
navir as the commonly used booster)
• Extreme caution should be applied, when 
associating other compounds to cART re-
gimens, with special reference for a seri-
es of antimicrobial agents, which are of 
frequent use just among HIV-infected pa-
tients, like:
 ∙ previously or concurrently administered 
antiretroviral agents, especially indina-
vir and tenofovir, but also boosted HIV 
protease inhibitors
 ∙ adefovir






 ∙ amphotericin B and its lipid derivatives
 ∙ glycopeptides
 ∙ interleukin-2
• Also to be considered when assessing in-
dividual HIV-infected patients:
 ∙ personal and familiar history for hyper-
tension of any origin, whatsoever renal 
disease, cardiovascular disorder, insulin-
resistance, and diabetes mellitus
 ∙ lifestyle (job, diet, cigarette smoking, 
physical exercise, etc.)
 ∙ acute or incidental or chronic pain 
(prompting the unadvertent use of pre-
scription and over-the-counter NSAIDs)
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nephrotoxic agents have been administered in the past, especially for a proportionally prolonged time. 
Some practical questions regarding the management of HIV-infected patients undergoing cART are 
briefly summarized in the box. An increased time between tenofovir administration has been recom-
mended in subjects with a severe kidney and also liver function impairment, where the potent antiviral 
activity of this compound has been successfully exploited also in these difficult-to-treat patients [142].
To conclude, a strategic approach to HIV infection management should enable all individuals living 
with HIV to aspire to a long life expectancy, with minimized end-organ compromise caused by both 
the virus, the cART, and underlying or concurrent diseases and/or treatments. 
Only a truly multidisciplinary team will be the best possible answer to these emerging and potentially 
life-threatening conditions, and the experiences shared between different Specialists will enrich both 
scientific and clinical expertise of everyone engaged to take care of HIV disease in its ever complicating 
scenario. This intricated situation, after the initial difficulties substantially confined to the proportio-
nally “narrow” point of view of each involved Specialist (with Clinical Infectious Diseases Specialist 
ranking first), is expected to become a very valuable resource, and a “real life”, ever moving experimen-
tal laboratory, and also a “training ground”, and a “work in progress” for Clinical Infectious Diseases 
caregivers, and all the Consultants Specialists who share the care of HIV-infected patients, which is 
becoming more difficult to manage, just when we have over 20 available anti-HIV drugs belonging to 
over six well developed pharmacological and therapeutic classes, depending on their mechanism of ac-
tion against HIV: i.e., nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase 
inhibitors, protease inhibitors, integrase inhibitors, fusion inhibitors, entry inhibitors), plus more and 
more antiretroviral drugs in their pipeline [143].
The “adventure” of HIV disease management and treatment, which started 30 years ago, in 1981 [131], 
had its first historical step at the time of viral recognition by Luc Montagnier and Robert C. Gallo in the 
year 1983 [117], then gained a subsequent step thanks to the possibility to measure plasma viral load as 
a major virological marker of disease progression monitoring, until we had got the first “triple thera-
pies” (HAART) available, since the mid-nineties [144,145], is now becoming more and more fascina-
ting, in its continued evolution concurrently with that of the available diagnostic and therapeutic re-
source, which have been discovered and developed by human beings since the year 1981, I their fight 
against HIV, which is now “entering its fourties”, so that a finally adult age.
The review in brief
Clinical question Revise and discuss causes of renal failure in HIV patients, with special attention to interactions between 
antiretroviral therapy and the even growing exposure to multiple different drug and drug classes
Type of review Narrative
Search of the 
literature
Medline search for English-language articles using the following keywords: HIV infection, antiretroviral 
treatment, tenofovir, acute renal failure, comorbidities, toxicity, drug surveillance
Conclusions A multidisciplinary vision and approach is mandatory for the diagnostic, clinical, and therapeutic 
management of kidney disorders occurring in patients living with HIV
Limitations The evolving subjects treated in this review deserve a continued update of informations coming 
from the international literature, with special reference to novel antiretroviral drugs approved for the 
management of HIV disease, and their potential (direct and indirect) interaction with kidney function
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